Research Peptides in Australia: Evaluating Suppliers and Verifying Purity
A reference guide to the analytical checks, documentation and storage standards used to assess research compound material, and what published market-surveillance studies have reported about products sold online.
Overview
Research peptides and research compounds are supplied in Australia almost entirely through online channels, and the analytical quality of that material is not uniform. Peer-reviewed market surveillance has repeatedly found that products sold online under research labelling frequently do not match their stated contents, purity or quantity.
This creates a practical problem for laboratory work: an unverified compound is an uncontrolled variable. If the identity, purity or actual mass of the material is unknown, every downstream measurement inherits that uncertainty. The checks described below are the ones that convert a supplier claim into a verifiable fact, and they are the basis on which research material is normally assessed.
This guide covers verification methodology and documentation standards only. It does not describe the biological activity of any specific compound. Compound-specific mechanism and literature references are held in the individual entries of the research library.
Quality Benchmarks at a Glance
How Purity and Identity Are Verified
Two analytical techniques carry most of the weight in research peptide characterisation. Each answers a different question, and neither is sufficient alone:
- Reversed-phase HPLC (purity): The sample is separated on a column and detected by UV absorbance, typically at 210-220 nm. A well-synthesised peptide resolves as a single dominant peak. Purity is reported as the area of that peak divided by the total area of all peaks, which is why the figure is expressed as a percentage rather than an absolute mass.
- Mass spectrometry (identity): HPLC establishes that a sample is homogeneous, not that it is the intended molecule. Mass spectrometry confirms that the dominant peak carries the expected molecular mass. A batch can be highly pure and still be the wrong compound, which is the failure mode observed in the market-surveillance literature below.
- Characteristic synthesis impurities: The minor peaks in a chromatogram are generally sequence-related by-products of solid-phase synthesis, including deletion sequences, truncated sequences, and products of incomplete deprotection or cleavage. Their profile is informative about how the material was made.
- Batch specificity: A certificate of analysis is only meaningful when it is tied to the batch actually supplied. A generic or undated certificate that is reused across production runs does not establish anything about the vial in hand.
Key Published Research
Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet
Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. JAMA. 2017; 318(20):2004-2010
Analytical study of 44 products purchased from internet vendors. The listed compound was detected in 52% of products, 39% contained a different unapproved drug, and no active compound at all was detected in 9%. The measured quantity matched the label in only 18 of the 44 products (41%). The most widely cited demonstration that online research-product labelling cannot be assumed accurate without independent analysis.
Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription
Ashraf AR, Mackey TK, Vida RG, et al. Journal of Medical Internet Research. 2024; 26:e65440
Market surveillance combined with laboratory testing of product purchased from unlicensed online sellers. Measured purity ranged from 7.7% to 14.37% against a 99% label claim, every vial tested positive for endotoxin (2.16 to 8.95 EU/mg), and packaging failed 59% to 63% of the quality criteria assessed. Illustrates that a stated purity figure with no supporting batch analysis carries no evidential weight.
Solid-state chemical stability of proteins and peptides
Lai MC, Topp EM. Journal of Pharmaceutical Sciences. 1999; 88(5):489-500
Review of the six degradation pathways that act on peptides in the dried state: deamidation, peptide bond cleavage, oxidation, the Maillard reaction, beta-elimination, and dimerisation or aggregation. Identifies temperature, residual moisture, formulation additives, and amorphous versus crystalline state as the controlling variables. The basis for cold, dry, sealed storage of lyophilised material.
Chemical pathways of peptide degradation VII: Solid state chemical instability of an aspartyl residue in a model hexapeptide
Oliyai C, Patel JP, Carr L, Borchardt RT. Pharmaceutical Research. 1994; 11(6):901-908
Controlled study of a lyophilised model hexapeptide examining how pH, temperature, moisture content and bulking agent influence solid-state degradation. Demonstrates that residual moisture in a lyophilised preparation is a measurable driver of degradation rate, not an incidental detail.
Storage and Handling
Storage conditions are part of quality control, not separate from it. Material that arrives at specification can drift out of it in the laboratory. Manning et al. (2010) review chemical and physical instability across both aqueous and dried states and the approaches used to stabilise each.
Lyophilised (unreconstituted):Store at -20°C for long-term stability. Stable at 2-8°C for shorter periods. Protect from light and moisture.
Reconstituted:Store at 2-8°C. Use within 30 days. Avoid repeated freeze-thaw cycles.
Recommended solvent: Bacteriostatic water or sterile water for laboratory use.
In transit: Lyophilised peptides tolerate short periods at ambient temperature, which is why they ship as dry powder rather than in solution. Vials should be moved to specified storage on arrival rather than left at room temperature.
Regulatory Status in Australia
The Australian Register of Therapeutic Goods (ARTG) is the register of therapeutic goods approved by the Therapeutic Goods Administration for supply in Australia. Research compounds of the type described in this library are not ARTG-listed and are not approved therapeutic goods. They are supplied for in-vitro research and laboratory use only, and are not for human or animal consumption.
Suppliers operating on this basis should state that status plainly rather than implying therapeutic approval. Any supplier presenting research material as a treatment, or providing human dosing guidance, is describing something the material is not approved for.
Frequently Asked Questions
What does a purity figure such as ≥98% actually mean?
It is a chromatographic area percentage. In an HPLC analysis the detector response is integrated across all resolved peaks, and the main peak is expressed as a proportion of that total. It describes how much of the detected material is the single dominant species. It is not a direct measure of the absolute mass of compound in the vial, which is why mass spectrometry and batch documentation are treated as complementary rather than optional.
What should a certificate of analysis contain?
At minimum: the compound name and sequence, a batch or lot identifier matching the vial supplied, the HPLC chromatogram and calculated purity, the mass spectrometry result with observed against theoretical mass, and the date of analysis. A certificate that lacks a batch identifier cannot be tied to the material received.
Why is lyophilised powder the standard supply form?
Peptides degrade considerably faster in solution than in the dried state. Removing water suppresses the hydrolytic and deamidation pathways that dominate in aqueous conditions, although the solid state has its own degradation routes governed by residual moisture and temperature (Lai and Topp, 1999). Shipping dry and reconstituting on site is the configuration that best preserves the material.
Are research compounds the same as pharmaceutical-grade products?
No. Pharmaceutical products are manufactured, tested and released under a regulatory approval framework and appear on the ARTG. Research compounds are characterised analytically for laboratory use and are not ARTG-listed or approved for human or animal use. The two categories are assessed against different standards and are not interchangeable.
Related Research References
- How to Reconstitute Peptides — solvent selection, concentration calculation, technique and post-reconstitution storage.
- BPC-157 and TB-500 — molecular profiles and published literature.
- GHK-Cu — tripeptide-copper complex research reference.
- MOTS-c vs NAD+ — comparative mechanism and literature reference.
Disclaimer: This information is compiled from published peer-reviewed literature and is provided for educational and research reference purposes only. It does not constitute medical advice. Compounds sold by Enhanced Research Compounds are intended exclusively for in-vitro research and laboratory use. They are not therapeutic goods, are not listed on the ARTG, and are not approved for human or animal consumption.